October 19, 2011 — Hologic Inc. announced the six-year follow-up results from the MammoSite Registry Study continue to show promising results for breast cancer patients. The results were presented at the American Society of Radiation Oncology (ASTRO) meeting in Miami, Florida, Oct. 3. The company featured its next-generation MammoSite ML (multi-lumen) radiation therapy.
The American Society of Breast Surgeons (ASBS) MammoSite Registry of more than 1,400 patients shows "excellent/good" cosmetic results in 90.4 percent of the cases. Hologic's MammoSite system is the only breast brachytherapy balloon system with six years of follow-up registry data.
According to Peter Beitsch, M.D., FACS, a surgeon at the Dallas Breast Center in Texas and lead author of the study, "The ASBS MammoSite Registry has contributed to the acceptance of accelerated partial breast irradiation (APBI) across this country and the world by the reassuring long-term data on local control, lack of risk of regional recurrence in the era of the sentinel node biopsy, and the comparable long-term survival after whole breast irradiation."
By employing MammoSite therapy, the radiation oncologist can deliver targeted radiation therapy directly to the area where cancer is most likely to recur, allowing a full course of radiation to be delivered in just five days. Additionally, targeted therapy of the breast limits radiation exposure to normal, healthy tissue. This targeting helps minimize side effects such as skin discoloration and scarring, burning, fatigue, and damage to surrounding organs. It also allows treatment of patients otherwise not appropriate candidates for traditional brachytherapy.
For more information: www.hologic.com
July 25, 2024 
